CClinicalTrials.gg
CompletedNCT04775628Updated Apr 7, 2022

Forces and Translation Distance During an Inferior Glide of the Shoulder

An interventional study of Inferior glide humerus in GH joint in Asymptomatic Condition, sponsored by Dr. Rob Sillevis,. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Dr. Rob Sillevis, · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jun 2018, registered Feb 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study evaluates the force and translation distance in the GH joint during a manual inferior glide of the humerus.

Read the detailed description

There has been limited research on how the variance of force affects MT outcomes and what the best practices of MT should be. No specific force threshold necessary to achieve a predetermined translational distance within the joint has been quantified within the literature. The purpose of this study was to quantify the amount of force necessary to perform an inferior glide to the glenohumeral joint and reach to end-range. A secondary aim was to determine the impact of co-variables, such as gender, height, weight, and age, on the amount of force required to translate the humeral head within the glenohumeral joint. Musculoskeletal Ultrasound imaging using the GE LogiQe was used to measure the translation of the humeral head. The manipulation force was measured using the Novel Pliance Glove device and software.

02

Conditions studied

  • Asymptomatic Condition

Browse trials for

Keywords

  • Manipulation force
  • Glenohumeral joint
  • Musculoskeletal Ultrasound Imaging
03

In context

Asymptomatic Diseases

36 studies on the registry are indexed under Asymptomatic Diseases; 8 are open to participants now.

This study's enrollment of 64 is above the median of 50 across 26 interventional studies indexed under Asymptomatic Diseases.

Browse Asymptomatic Diseases studies →

Lead sponsor

This is the only study on the registry with Dr. Rob Sillevis, as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy volunteers
  • Able to read the English language fluently

Exclusion criteria

Exclusion Criteria:

  • a history of injury of the right shoulder
  • right shoulder surgery
  • presence of shoulder pain
  • comorbidities affecting natural ROM within the dominant shoulder
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    inferior glide

    Inferior glide of the right humerus till no motion is visual on the imaging

    Procedure: Inferior glide humerus in GH joint

Interventions

  • ProcedureInferior glide humerus in GH joint

    Supine inferior glide GH joint

06

What researchers measure

Primary outcomes

  1. Translation

    Measured in mm using MSK Ultrasound

    Time frame: 5 minutes

  2. Force measure

    Force measure during inferior glide using Novel Pliance Glove

    Time frame: 5 minutes

07

Study locations

1 site
  • Florida Gulf Coast University
    Fort Myers, Florida 33965, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04775628
Lead sponsor
Dr. Rob Sillevis,
Collaborators
Mitchell Todd, J.P Speare, Eric Shamus, Arie van Duijn
Responsible party
Dr. Rob Sillevis, (Assistent Professor, Florida Gulf Coast University) — Sponsor-investigator
First posted
Mar 1, 2021
Start date
Jun 1, 2018
Primary completion
Nov 1, 2018
Completion
May 1, 2019
Last update
Apr 7, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion